Skip to content

9 mg/ml

DRUG11 trials

Sponsors

Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A., Lipigon Pharmaceuticals AB, Medical University Of Gdansk, Nicolaus Copernicus University, AstraZeneca AB

Conditions

Breathing disorders as a cause of neonatal respiratory failureCOVID-19 and other pulmonary parenchyma infections.Diabetic foot ulcers infected by Acinetobacter baumanniiHeart failure with reduced ejection fractionModerate to severe hypertriglyceridemiaPseudomonas aeruginosa and /or Staphylococcus aureusRecent myocardial infarction associated with iron deficientRenal impairment

Phase 1

Phase 2

A Phase 2b Clinical Study to Evaluate the Safety and Efficacy of Topical Administration of Bacteriophage Therapy TP-102 in Patients with Diabetic Foot Infection
CompletedCTIS2023-507716-13-00
Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.Diabetic foot ulcers infected by Acinetobacter baumannii, Pseudomonas aeruginosa and /or Staphylococcus aureus
End: 2025-12-19Target: 26Updated: 2025-08-18
A phase 2, randomised, double-blind, placebo-controlled trial to evaluate safety and local tolerability of four weekly administrations of A24110He in subjects with elevated triglyceride plasma concentrations
CompletedCTIS2023-509091-42-00
Lipigon Pharmaceuticals ABModerate to severe hypertriglyceridemia
Start: 2024-02-27End: 2026-01-08Target: 26Updated: 2025-07-04
Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of nandrolone decanoate therapy and therapy with complex physiotherapy and diet in the treatment of sarcopenia
RecruitingCTIS2024-517178-48-00
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicherand mortality in older adults., deterioration and quality of life, falls and injuries +3
Start: 2023-03-15Target: 168Updated: 2024-10-31
ITPP as an adjunctive treatment for progressive respiratory failure in COVID-19 and other pulmonary parenchymal infections - a randomized, double-blind, non-commercial phase II clinical trial [BREATH2]
CompletedCTIS2024-517878-21-00
Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyCOVID-19 and other pulmonary parenchyma infections.
Start: 2023-11-28End: 2025-06-11Target: 100Updated: 2025-02-10
Comparison of treatment efficacy in the patients with Systemic sclerOsis: dapagliFlozin vs. Tocilizumab – a randomized head to head study
WithdrawnCTIS2025-523714-92-00
Centrum Medyczne Ksztalcenia PodyplomowegoSystemic Sclerosis
Target: 80Updated: 2025-12-15

Phase 3

Phase 4